Premium
IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α
Author(s) -
Yamagata Noboru,
Shimazaki Chihiro,
Goto Hideo,
Hirata Toshiyuki,
Ashihara Eishi,
Oku Naritoshi,
Inaba Tohru,
Fujita Naohisa,
Nakagawa Masao
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830450315
Subject(s) - melphalan , plasma cell leukemia , prednisolone , vincristine , dexamethasone , medicine , doxorubicin , multiple myeloma , leukemia , plasma cell myeloma , chemotherapy , daunorubicin , immunology , cancer research , oncology , cyclophosphamide
A 69‐year‐old woman with IgE/K plasma cell leukemia (PCL) was treated with a sequential combination of VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐α (IFNα). A complete remission was achieved for 14 months. Maintenance therapy with IFNα has continued for an additional 10 months. IgE PCL Is extremely rare. The biological characteristics of the myeloma cells, including surface marker, adhesion molecule, karyotype, DNA analysis, and the response to various cytokines, are presented. © 1994 Wiley‐Liss, Inc.